Tripping on nothing: placebo psychedelics and contextual factors

Psychedelic experiences are shaped not only by pharmacology but also by non-pharmacological factors such as mindset, expectations, and environment (the so-called "set and setting"). Olson and colleagues note that although placebo effects occur across many domains, placebo arms in psychedelic research have generally shown few effects, which may reflect laboratory settings, study design choices, or analytic practices that obscure individual responses. The authors draw attention to the phenomenon of "contact highs"—drug-like effects experienced without ingestion, reported in naturalistic groups—and argue that such effects have been little studied despite plausible mechanisms including classical conditioning, social modelling, and emotional contagion. This feasibility study set out to test whether a placebo could produce psychedelic-like subjective experiences when delivered in a naturalistic, party-like context with strong expectation manipulations and social modelling. Specifically, the investigators hypothesised that at least some participants would report alterations in consciousness after ingesting an inert capsule that they were led to believe contained a fast-acting psilocybin analogue, and they emphasised examining individual variation rather than group averages.

The study recruited university students via social media for what was presented as research on a psychoactive drug's effects on creativity. After phone screening to confirm student status and absence of physical or mental health issues, 33 participants attended two evening sessions (sample 1 n = 16; sample 2 n = 17). Mean age was 21.7 years (SD = 3.4) and 18 were men. The protocol excluded psychology students at the host institution; an initial attempt to exclude prior psychedelic users was abandoned for the second sample after some participants concealed past use. Institutional review board approval was obtained. To maximise credibility and expectations, the experiment used an elaborate deception procedure. Participants met at the institute lobby, received wristbands and name tags, and were escorted to a dimly lit room arranged like a psychedelic party: coloured lights, psychedelic paintings with subtle illusions, ambient music played by a DJ, film projections with vivid visuals, cushions, drawing materials, snacks, and multiple researchers in lab coats. Confederates (6–7 per sample) embedded in the group were instructed to subtly model and then amplify drug-like effects. A psychiatrist and numerous staff contributed to the appearance of a legitimate multi-site study. Each participant individually received a size 0 pink capsule filled with microcrystalline cellulose, described as "iprocin," a psilocybin homologue. Dosage and expected effects (mood, hallucinations, sensory changes, etc.) had been conveyed during screening and briefing. Physiological feedback was manipulated: a baseline heart rate and blood pressure reading was read aloud 10 units lower than actual, and a later reading was increased by 10 units to imply drug-induced change. Interactions, mingling periods, and creativity tasks maintained the cover story and provided contexts in which placebo effects might be noticed. Primary subjective outcome measurement was the 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC), administered before and after ingestion. The Positive and Negative Affect Schedule (PANAS) and several filler measures (Big Five Inventory, Remote Associates Test, a divergent association task, and a brief drawing task) were also collected. Two participants with unusually high pre-drug 5D-ASC scores were excluded from analyses of that scale. Analysis was exploratory and descriptive: the investigators focused on individual differences and did not perform inferential statistical tests.

Individual responses varied widely. On the 5D-ASC some participants reported alterations in conscious experience on subscales at magnitudes comparable to those typically associated with moderate or high doses of psilocybin or to moderate doses of LSD, while many others reported minimal change; group averages remained low. The extracted text does not clearly report all mean subscale values, but the authors emphasise the breadth of individual outcomes rather than a central tendency. Verbal reports indicated that 61% of participants spontaneously reported some effect of the purported drug during the session. Reported effects ranged from sensory and perceptual changes (e.g. paintings "moving" or "reshaping themselves," heightened colours or sounds, complex imagery with eyes closed) to bodily sensations (feeling heavy, warm, or a "chemical tingling") and altered cognition or affect (increased openness, ease of thought, time dilation, or transient laughter). Several examples are given, including one participant who described alternating waves of intensity and a subjective ability to "bring it upon [herself] again." Negative placebo (nocebo) experiences were also reported, such as nausea, headaches, and sinking or low-energy sensations. The remaining 39% reported nothing unusual. When asked at the end of the second sample about prior classical psychedelic use, 6 reported prior use, 10 reported none, and 1 did not answer. Within that sample, 50% [19%, 81%] of those with prior use verbally reported effects and 70% [35%, 92%] of those without prior use did so; average 5D-ASC scores for naïve participants were reported as 3.59 [0.69, 7.37], while the corresponding value for experienced users is not clearly reported in the extracted text. Participants' mood on the PANAS declined for both positive and negative affect across the session, with the "excited" and "nervous" items showing the largest drops, suggesting diminution of initial arousal or anticipatory tension; specific baseline and endpoint PANAS means are not clearly legible in the extraction. Physiological measures showed no major changes: mean heart rate moved from 82 to 78 bpm, systolic blood pressure from 134 to 128 mm Hg, and diastolic from 81 to 80 mm Hg. Prior to debriefing in the second sample, 35% of participants reported being certain they had taken a placebo, 12% were certain they had taken a psychedelic, and 53% were uncertain. Two participants with outlying pre-drug 5D-ASC scores had been excluded from that scale's analysis.

Olson and colleagues interpret their findings as evidence that contextual factors and expectations can produce robust psychedelic-like subjective effects even in the absence of a psychoactive drug. They emphasise that some participants in this deliberately maximised-context design reported altered states comparable to moderate or high drug doses, and the study thus demonstrates the potential strength of placebo and contact-high phenomena when social modelling, environmental cues, and explicit expectation manipulation are combined. The investigators situate these results with respect to microdosing and other areas where the placebo component may be important, recommending designs that can disentangle pharmacological and expectation effects. In particular, they endorse the balanced placebo 2 × 2 design—crossing what participants are told with what they receive—as a way to isolate expectation, and they note that an active placebo (producing mild physiological sensations) could further sustain belief in drug ingestion. The authors also propose clinical implications: enhancing non-pharmacological components of treatment (for example, via videos that facilitate social modelling) might amplify therapeutic outcomes and potentially allow effective use of lower drug doses, which could improve safety. Limitations acknowledged by the study team include the lack of a control group that varied contextual features, which prevents attributing effects to specific manipulations; some participants showed elevated alterations before ingestion, indicating that the environment itself may produce effects and that the pre-drug measurement may have influenced expectations; and the modest sample size and practical difficulty of recruiting further participants once word spread across campus. The authors call for future research incorporating objective or behavioural measures, different control conditions (including open-label placebos), and balanced placebo designs to isolate mechanisms. They also urge psychedelic researchers to report individual-level placebo or low-dose responses, provide richer descriptions (and ideally photographs) of setting and experimenter behaviour, and disclose the list of expected effects communicated to participants, because such details can shape expectations and thereby influence outcomes. Overall, the authors recommend viewing placebo responses not merely as nuisance variance but as informative evidence of how context can modulate or even create aspects of the psychedelic experience.